Posted by Michael Wonder on 09 Aug 2021
Scotland backs Bavencio for bladder cancer after NICE says no
9 August 2021 - Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance treatment with Merck Serono and Pfizer’s Bavencio, ahead of their counterparts in England and Wales.
The SMC has cleared NHS funding for Bavencio (avelumab) as a first-line maintenance therapy for people with advanced urothelial carcinoma – the most common form of bladder cancer – that has not progressed after initial chemotherapy.
